PRESS RELEASE: Fitch Affirms GlaxoSmithKline at 'A+'; Outlook Stable
5th Jul 2010 16:34
Fitch Ratings-London-05 July 2010: Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default (IDR) and senior unsecured ratings at 'A+' and its Short-term IDR at 'F1'. GlaxoSmithKline's commercial paper programme is also affirmed at 'F1'. The Ou
Read morePRESS RELEASE: New data provides additional support confirming CERVARIX(TM) demonstrated protection against HPV type 45, linked with the most aggressive form of cervical cancer
5th Jul 2010 12:13
MISSISSAUGA, ON, July 5 /CNW/ - The end-of-study results of the largest efficacy trial of a cervical cancer vaccine presented at a major international congress provides additional support confirming that CERVARIX(TM) demonstrated protection against human papillomavirus (HPV) types 18 and 45(1), whic
Read morePRESS RELEASE: New data provides additional -2-
5th Jul 2010 12:13
/CONTACT: or to arrange an interview, please contact: Marlo Taylor, for GSK, 416-645-3656, [email protected]; GlaxoSmithKline Inc., Corporate Communications, 905-819-3363 Copyright CNW Group 2010 (END) Dow Jones Newswires July 05, 2010 07:13 ET (11:13 GMT)
Read moreMARKET TALK: Genmab Seen Opening Up On Adjusted GSK Deal
2nd Jul 2010 07:36
0636 GMT [Dow Jones] Genmab's (GEN.KO) shares should open sharply higher after the company said late Thursday it has amended its co-operation agreement for the drug Arzerra with partner GlaxoSmithKline (GSK), says analyst Rune Majlund Dahl at Sydbank. Says Genmab receives money upfront so it can imp
Read moreGlaxoSmithKline, Genmab Announce Amendment To Ofatumumab Pact
1st Jul 2010 17:19
DOW JONES NEWSWIRES GlaxoSmithKline and Genmab Thursday said they had made an amendment to the ofatumumab co-development and commercialization agreement. MAIN FACTS: -GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofat
Read morePRESS RELEASE: GlaxoSmithKline and Genmab Announce Amendment to Ofatumumab Agreement
1st Jul 2010 17:16
LONDON and COPENHAGEN, Denmark, July 1 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE and LSE: GSK) and Genmab A/S (OMX: GEN) announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing
Read moreGlaxoSmithKline Forms New Unit For Least Developed Countries
1st Jul 2010 16:17
LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global healthcare group, announced Thursday it has created a new operating unit dedicated to expanding access to medicines for people living in the Least Developed Countries or LDCs. MAIN FACTS: -A new Developing Countries and Market Access
Read moreMARKET TALK: Drug-Cargo Thefts, Detailed
30th Jun 2010 20:15
3:15 (Dow Jones) That $75M heist at Eli Lilly's (LLY) drug warehouse in March was big news, but it was just one of several high-value thefts to hit the industry recently. The blog FiercePharmaManufacturing.com has detailed report this week about top drug cargo thefts, which lists separate incidents
Read moreUK SMALLCAP ROUNDUP: Resaca Exploration Shelves Share Sale
30th Jun 2010 16:00
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps RESACA EXPLOITATION INC. (RSOX.LN), an oil and gas company, said Wednesday it postponed a planned share issue due to market conditions. Resaca planne
Read moreLondon close: Flat finish
30th Jun 2010 15:56
A jumpy start on Wall Street did nothing to steady a volatile Footsie, but despite all the fluctuations the leading index finished hardly changed on the day. London lost 272 points in June, the third monthly decline in a row, and traded a range of well over 400 points. Miners ENRC, Kazakhmys and A
Read moreLondon afternoon: Miners spoil the party
30th Jun 2010 14:15
The Footsie turned south over the lunch time session as traders took note of the US stock futures market which indicates US markets will open mixed and miners took a turn for the worse. Anglo-Swedish drugs giant AstraZeneca is still the best performer after it received a favourable US ruling in it
Read moreUK SMALLCAP ROUNDUP: HMV Strategy On Track Amid Record Sales
30th Jun 2010 12:30
Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps HMV GROUP PLC (HMV.LN) Wednesday said its strategy of diversifying its business away from CDs and DVDs remains on track, although the CD market didn't de
Read moreLondon midday: Respectable gains for Footsie
30th Jun 2010 11:58
Gains in London are now approaching respectable, buoyed by strong demand for heavy hitters in the pharmaceuticals and energy sectors. Anglo-Swedish drugs giant AstraZeneca is the best performer after it received a favourable US ruling in its battle to keep control of the patents to its best-selling
Read moreFutura Medical Signs Development Deal With GlaxoSmithKline
30th Jun 2010 08:56
LONDON (Dow Jones)--Pharmaceutical company Futura Medical PLC (FUM.LN) Tuesday said it signed a deal with GlaxoSmithKline PLC's (GSK.LN) cosumer healthcare unit to develop a painkiller. GlaxoSmithKline will be responsible for the clinical and regulatory development of Futura's TR100 and Futura w
Read moreMARKET TALK: Avandia Studies' Impact On GSK Modest
28th Jun 2010 17:31
12:31 (Dow Jones) GlaxoSmithKline (GSK) shares down 0.5% at $34.43 after release of two new studies reinforcing safety concerns about diabetes drug Avandia. From investor standpoint, much of Avandia-related damage was previously baked in over past few years. Avandia sales in 2009 were only 2.7% of t
Read more